

# Appendix

## Q1 2026 Financial Results

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	March 31, 2026	March 31, 2025
<b>Reconciliation of GAAP to Non-GAAP Research and development expenses:</b>		
GAAP Research and development expenses	\$ 364,866	\$ 265,122
Less: Stock-based compensation expenses	(30,112)	(23,798)
Non-GAAP Research and development expenses	<u>\$ 334,754</u>	<u>\$ 241,324</u>
<b>Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses:</b>		
GAAP Selling, general and administrative expenses	\$ 322,551	\$ 239,949
Less: Stock-based compensation expenses	(40,042)	(32,914)
Non-GAAP Selling, general and administrative expenses	<u>\$ 282,509</u>	<u>\$ 207,035</u>
<b>Reconciliation of GAAP to Non-GAAP Income (loss) from operations:</b>		
GAAP Income from operations	\$ 268,636	\$ 18,077
Add: Stock-based compensation expenses	70,154	56,712
Non-GAAP Operating income	<u>\$ 338,790</u>	<u>\$ 74,789</u>
<b>Reconciliation of GAAP to Non-GAAP Net income (loss):</b>		
GAAP Net income (loss)	\$ 205,991	\$ (18,251)
Add: Stock-based compensation expenses	70,154	56,712
Add: Realized and unrealized loss on marketable equity securities	—	956
Less: Income tax effect of GAAP to non-GAAP reconciling items	(3,107)	(1,476)
Non-GAAP Net income	<u>\$ 273,038</u>	<u>\$ 37,941</u>

Please note that the figures presented above may not sum exactly due to rounding



# Anylam Pharmaceuticals, Inc.

## Reconciliation of Product Revenue and Growth at Constant Currency

	<b>March 31, 2026</b>
	<b>Three Months Ended</b>
AMVUTTRA net product revenue growth, as reported	187 %
Add: Impact of foreign currency translation	(4)
AMVUTTRA net product revenue growth at constant currency	<u>183 %</u>
ONPATTRO net product revenue growth, as reported	(59)%
Add: Impact of foreign currency translation	(2)
ONPATTRO net product revenue growth at constant currency	<u>(61)%</u>
Total TTR net product revenue growth, as reported	153 %
Add: Impact of foreign currency translation	(3)
Total TTR net product revenue growth at constant currency	<u>150 %</u>
GIVLAARI net product revenue growth, as reported	11 %
Add: Impact of foreign currency translation	(4)
GIVLAARI net product revenue growth at constant currency	<u>7 %</u>
OXLUMO net product revenue growth, as reported	22 %
Add: Impact of foreign currency translation	(9)
OXLUMO net product revenue growth at constant currency	<u>13 %</u>
Total Rare net product revenue growth, as reported	15 %
Add: Impact of foreign currency translation	(5)
Total Rare net product revenue growth at constant currency	<u>10 %</u>
Total net product revenue growth, as reported	121 %
Add: Impact of foreign currency translation	(4)
Total net product revenue growth at constant currency	<u>117 %</u>
Total revenue growth, as reported	96 %
Add: Impact of foreign currency translation	(3)
Total revenue growth at constant currency	<u>93 %</u>